Efficacy of Infliximab in Patients with Refractory Uveitis Associated with Behcet Disease

F, Nilufer Yalcındag

doi:10.4172/2155-9570.1000319

Cited by 2 publications

(2 citation statements)

References 16 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For OBD, systemic or local corticosteroids are advised; when insufficient, systemic immunomodulatory therapy [8,18,19,23,24] and tumor necrosis factor alpha (TNF-α) inhibitor [11,22]. Even with intensive immunosuppressive therapy, however, ocular inflammation may relapse in about 70% of patients, resulting in permanent loss of vision.…”

Section: Treatment Of Ocular Bdmentioning

confidence: 99%

Refractory Ocular Behçet’s Disease; Outcome of Low Dose Infliximab

Ferdous¹,

Islam

Rahman³

et al. 2019

Rheum Res

View full text Add to dashboard Cite

A 40-year-old woman had been suffering from many symptoms of Behçet's disease (BD) since her childhood without being diagnosed. She had recurrent mouth ulcers and, from the age of 21, vulva ulcers followed by loss of vision due to central retinitis and later also ankle arthritis. At the age of 31, uveitis due to BD was diagnosed. The fact that BD is often not recognized in Bangladesh explains the marked delay in her diagnosis. The initial central retinitis responded well to oral glucocorticoids, azathioprine, and cyclosporine, but in the course of time she became refractory to these agents. Considering her financial constraints, low dose Infliximab (3mg/kg) was used and resulted in a remarkable but temporal improvement. She went into remission by using a regimen of 5 mg/kg with increased interval time. In this article, the treatment options for ocular involvement in BD patients are summarized. Conclusions: In countries like Bangladesh, the diagnosis of Behçet's disease can be delayed. The early cooperation of dermatologists and eye surgeons with rheumatologists is necessary. Most cases of resistant ocular BD today can be successfully treated with anti-TNF agents. Promising results are published with other biologics for refractory and multi-resistant cases.

show abstract

Section: Treatment Of Ocular Bdmentioning

confidence: 99%

Refractory Ocular Behçet’s Disease; Outcome of Low Dose Infliximab

Ferdous¹,

Islam

Rahman³

et al. 2019

Rheum Res

View full text Add to dashboard Cite

show abstract

“… 31 It is also effective in the treatment of BU and intermediate uveitis. 70 , 71 , 72 The most common complication associated with interferon therapy is influenza-like symptoms. In fact, the resolution of these symptoms suggests the formation of anti-interferon antibodies.…”

Section: Introductionmentioning

confidence: 99%

COVID-19 and the Use of Immunomodulatory Agents in Ophthalmology

Değirmenci¹,

Yalçındağ²,

Tuğal-Tutkun³

2021

tjo

View full text Add to dashboard Cite

Immunomodulatory agents are often used in the systemic treatment of non-infectious uveitis. These drugs consist of corticosteroids, conventional immunosuppressives, and biological agents. As it is known that they suppress the immune system, the most important concern associated with immunomodulatory therapy (IMT) is the increased risk of infection. The World Health Organization declared COVID-19 a pandemic on 11 March 2020. Although severe acute respiratory distress syndrome secondary to SARS-CoV-2 infection may develop in all people, patients who receive IMT may be at higher risk in terms of both the transmission of the infection and more severe disease course. Therefore, guidelines on the management of patients receiving IMT due to uveitis during the pandemic are needed. In this review, we examined the immunomodulatory drugs used in the treatment of uveitis in terms of infectious complications and the data of patients who received IMT during the COVID-19 pandemic and discussed recommendations for the use of these drugs. According to the latest information, patients who receive IMT may continue their treatment as long as there are no disruptions in regular complete blood count (especially white blood cell count >4,000/μL) and liver and kidney function tests. Patients diagnosed with COVID-19 should be managed with a multidisciplinary approach.

show abstract

Efficacy of Infliximab in Patients with Refractory Uveitis Associated with Behcet Disease

Cited by 2 publications

References 16 publications

Refractory Ocular Behçet’s Disease; Outcome of Low Dose Infliximab

Refractory Ocular Behçet’s Disease; Outcome of Low Dose Infliximab

COVID-19 and the Use of Immunomodulatory Agents in Ophthalmology

Contact Info

Product

Resources

About